SEC Form 4 · accession 0001140361-18-018863
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Murray
Officer — President & CEO · Director
Period of report
Apr 16, 2018
Accepted (ET)
Apr 17, 2018 · 8:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Apr 17, 2018 | M | 27,007 | $0.354 | A | 316,396 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $5.20 | Apr 16, 2018 | A | 418,187 | A | — | Apr 16, 2028 | Common Stock | 418,187 | 418,187 | D |
| Employee Stock Option (Right to Buy)F2,F3 | $0.354 | Apr 17, 2018 | M | 27,007 | D | Mar 30, 2008 | Mar 1, 2018 | Common Stock | 27,007 | 0 | D |
Explanation of responses
- F1The options vest as follows: 1/3 on April 16, 2019; 1/3 on April 16, 2020; and 1/3 on April 16, 2021.
- F2Converted from Canadian exercise price of $0.4444; Cdn$1.2552=US$1.00.
- F3Expiration date extended through termination of blackout period.